What is the recommended assessment and treatment for a patient with suspected gout?

Assessment and Treatment for Suspected Gout

For suspected gout, diagnose clinically based on typical presentation (acute monoarticular arthritis, especially first MTP joint) with elevated serum uric acid, then immediately treat the acute flare with NSAIDs, colchicine, or corticosteroids while simultaneously initiating low-dose allopurinol (≤100 mg/day) with anti-inflammatory prophylaxis for 3-6 months 1.

Diagnostic Assessment

Clinical Diagnosis

In primary care settings, gout can be diagnosed without joint aspiration when the clinical picture is typical 2, 3:

• Acute monoarticular arthritis (especially first metatarsophalangeal joint, ankle, or knee)
• Rapid onset of severe pain, swelling, erythema
• Elevated serum uric acid (though normal levels don't exclude gout during acute flare)
• History of prior similar episodes
• Presence of cardiovascular/metabolic comorbidities (obesity, hypertension, chronic kidney disease)

Common pitfall: Only ~11% of suspected gout patients undergo joint aspiration in practice 3. While definitive diagnosis requires demonstrating monosodium urate crystals under polarized light microscopy, this is not mandatory when presentation is classic.

When to Pursue Advanced Diagnostics

For atypical presentations, consider 4, 5:

• Joint aspiration with polarized light microscopy (gold standard)
• Ultrasound showing double contour sign or tophi
• Dual-energy CT demonstrating urate crystal deposition

Acute Flare Treatment

Initiate anti-inflammatory therapy immediately with one of these first-line options 1:

• NSAIDs (if no contraindications)
• Colchicine
• Corticosteroids (oral prednisone/prednisolone or intra-articular)

Choice depends on patient-specific factors including renal function, cardiovascular disease, and gastrointestinal risk.

Urate-Lowering Therapy (ULT)

When to Start

Start ULT during the acute flare rather than waiting for resolution 1. This conditional recommendation reflects that delaying treatment provides no benefit and prolongs time to achieving target uric acid levels.

First-Line ULT: Allopurinol

Allopurinol is the strongly recommended first-line agent for all patients, including those with CKD stage ≥3 1:

• Starting dose: ≤100 mg/day (even lower with CKD, consider ≤50 mg/day)
• Titration: Gradually increase every 2-4 weeks
• Target dose: Often requires >300 mg/day, up to maximum 800 mg/day
• Goal: Serum uric acid <6 mg/dL (some sources suggest 180-300 μmol/L for chronic gout) 6

Rationale: Low starting doses mitigate allopurinol hypersensitivity syndrome risk while allowing safe dose escalation to achieve target uric acid levels 1.

Alternative ULT Options

Febuxostat (if allopurinol contraindicated/not tolerated):

• Start ≤40 mg/day with titration
• Also preferred as xanthine oxidase inhibitor over probenecid in CKD stage ≥3 1

Probenecid:

• Start 500 mg once or twice daily with titration
• Avoid in moderate-to-severe CKD 1

Pegloticase is strongly recommended AGAINST as first-line therapy due to cost, safety concerns, and need to exhaust oral options first 1.

Mandatory Flare Prophylaxis

Strongly recommended: Initiate concomitant anti-inflammatory prophylaxis when starting ULT 1:

• Duration: 3-6 months minimum (NOT <3 months)
• Options: Colchicine, NSAIDs, or low-dose prednisone/prednisolone
• Continue longer if patient continues experiencing flares

This prevents the paradoxical flares that occur when initiating ULT due to urate crystal mobilization.

Essential Comorbidity Management

Critical consideration: Most gout patients have cardiovascular, metabolic, and renal comorbidities that contribute more to mortality than gout itself 2, 7. Therefore:

• Assess cardiovascular risk factors at diagnosis
• Check renal function (affects ULT dosing)
• Screen for metabolic syndrome, diabetes, hypertension
• Consider SGLT2 inhibitors for patients with appropriate comorbidities (uricosuric side effect provides additional benefit) 2

Treatment Algorithm Summary

1. Diagnose clinically if typical presentation + elevated uric acid
2. Treat acute flare immediately (NSAID/colchicine/corticosteroid)
3. Start allopurinol ≤100 mg/day during the flare (lower if CKD)
4. Add prophylaxis (colchicine/NSAID/prednisone) for 3-6 months minimum
5. Titrate allopurinol every 2-4 weeks to achieve uric acid <6 mg/dL
6. Address comorbidities (cardiovascular, metabolic, renal)
7. Monitor adherence long-term (chronic disease requiring indefinite treatment)

Key pitfall to avoid: Starting allopurinol at high doses without prophylaxis—this virtually guarantees severe flares and treatment abandonment. The low-and-slow approach with prophylaxis is strongly evidence-based 1.